← Back to Search

Other

TRPV6 Calcium Channel Inhibitor SOR-C13 for Pancreatic Cancer

Phase 1
Waitlist Available
Led By Siqing Fu
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial examines the side effects and optimal dose of SOR-C13 in patients with advanced solid tumors that have not responded to other treatments. SOR-C13 aims to block a pathway in cancer cells to prevent their growth and spread.

Eligible Conditions
  • Pancreatic Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Solid Tumors
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events and serious adverse events
Secondary study objectives
Clinical benefit
Objective responses
Predictive biomarkers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (TRPV6 calcium channel inhibitor SOR-C13)Experimental Treatment1 Intervention
Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SOR-C13
Not yet FDA approved

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,054 Previous Clinical Trials
1,798,873 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,887 Previous Clinical Trials
41,021,017 Total Patients Enrolled
Siqing FuPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
531 Total Patients Enrolled
~2 spots leftby Oct 2025